Summary
EW Chart
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript
Edwards Lifesciences Corporation ( EW ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Daniel Lippis - Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Conference Call Participants Travis Steed - BofA Securities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Taylor - Jefferies LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Presentation Operator Greetings, and welcome to the Edwards Lifesciences' Third Quarter 2025 Conference Call. [Operator Instructions] Please note, this conference is being recorded.
Edwards Lifesciences (EW) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
East West Banking Corporation (EW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has East West Banking Corporation ever had a stock split?
East West Banking Corporation Profile
| - Industry | - Sector | Bernard J. Zovighian CEO | XPHS Exchange | PHY223581083 ISIN |
| US Country | 15,800 Employees | - Last Dividend | 1 Jun 2020 Last Split | 27 Mar 2000 IPO Date |
Overview
Edwards Lifesciences Corporation specializes in providing advanced medical technologies tailored to diagnose and treat structural heart diseases and conditions requiring critical care monitoring. The company has a global footprint, offering its state-of-the-art products and solutions across the United States, Europe, Japan, and other international markets. Founded in 1958, Edwards Lifesciences has its headquarters in Irvine, California, and leverages both a direct sales force and a network of independent distributors to reach its market.
Products and Services
- Transcatheter Heart Valve Replacement Products:
Under the Edwards SAPIEN family, these products offer minimally invasive options for replacing aortic heart valves, enabling significant improvements in patient outcomes and recovery times.
- Transcatheter Heart Valve Repair and Replacement Products:
Targeting mitral and tricuspid valve diseases, products under the PASCAL PRECISION and Cardioband names offer advanced solutions for valve repair and replacement, supporting heart function restoration.
- Surgical Structural Heart Solutions:
Edwards provides various surgical solutions including the INSPIRIS aortic surgical valve and the INSPIRIS RESILLA valve, featuring RESILIA tissue and VFit technology for enhanced durability. The KONECT RESILIA and MITRIS RESILIA valve products support complex procedures with pre-assembled tissue valves and innovative designs for better patient outcomes.
- Critical Care Solutions:
The company's critical care portfolio includes hemodynamic monitoring systems such as FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight, designed to measure heart function and fluid status in surgical and ICU settings accurately. The HemoSphere monitoring platform visually displays critical physiological information, and the Acumen Hypotension Prediction Index software utilizes advanced algorithms to predict and alert clinicians of potential dangerous drops in blood pressure.
Contact Information
